|
시장보고서
상품코드
2020270
암 진단 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)Cancer Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
암 진단 시장 성장 요인
세계 암 진단 시장은 암 부담 증가, 진단 기술의 발전, 조기 발견을 촉진하기 위한 정부의 이니셔티브 증가로 인해 견고한 성장세를 보이고 있습니다. 최근 데이터에 따르면, 시장 규모는 2025년에 172억 4,000만 달러로 평가되었고, 2026년에는 185억 1,000만 달러에 달할 것으로 예측됩니다. 2034년까지 시장은 382억 7,000만 달러로 크게 확대될 것으로 예상되며, 2026-2034년 연평균 9.5%의 성장률을 보일 것으로 예측됩니다.
시장 성장 촉진요인
유방암, 대장암, 전립선암 등의 발병률 증가는 효과적인 진단법에 대한 수요를 촉진하는 주요 요인입니다. 예를 들어, 세계보건기구(WHO)에 따르면, 전 세계 신규 암 환자 수는 2025년까지 3,500만 명에 달할 것으로 예상되며, 이는 2022년 2,000만 명에서 77% 증가한 수치입니다. 조기 및 정확한 진단은 사망률 감소에 매우 중요한 역할을 하고 있으며, 이는 면역조직화학(IHC), in situ hybridization(ISH), 분자진단, 액체생검 등 첨단 진단 솔루션의 도입을 가속화하고 있습니다.
정부와 민간단체는 암 조기발견에 대한 인식 개선을 위한 노력을 강화하고 있습니다. 미국의 ACCION(Against Colorectal Cancer in Our Neighborhoods), 영국의 BCSP(Bowel Cancer Screening Programme), WHO의 자궁경부암 퇴치를 위한 세계 전략과 같은 프로그램들은 검진 및 조기 개입을 확대하는 것을 목표로 하고 있습니다. 이러한 노력은 진단 기술 도입을 촉진하여 시장 성장을 가속하고 있습니다.
시장 성장 억제요인
성장세가 예상되는 반면, 진단 절차에 따른 높은 비용과 특정 리스크는 여전히 과제로 남아있습니다. 예를 들어, 대장암 검진의 표준인 대장내시경 검사는 출혈, 천공, 기구 관련 감염 등의 위험이 있습니다. 또한, PCR 장비와 같은 고급 진단 장비는 3,000달러에서 3만 달러에 달하고, 지속적인 유지보수 비용이 발생하기 때문에 특히 신흥 시장에서의 도입이 제한적입니다.
시장 기회
아시아태평양의 신흥 시장에서는 의료 인프라에 대한 정부 투자 증가와 원격의료에 대한 인식이 높아지면서 성장 기회가 창출되고 있습니다. 코로나19 팬데믹은 원격의료의 도입을 가속화하고, 암 검진이나 진찰을 원격으로 할 수 있게 했습니다. 이러한 추세는 앞으로도 계속될 것으로 예상되며, 의료 서비스를 충분히 받지 못하는 사람들에게 조기 진단과 경과 관찰에 대한 접근성을 제공하게 될 것입니다.
시장 동향
시장 기업은 제품 출시, 기술 발전 및 파트너십에 점점 더 집중하고 있습니다. 주요 동향은 다음과 같습니다.
- 2022년 6월: F. 호프만 라 로슈는 암의 조기 진단을 강화하기 위해 'BenchMark ULTRA PLUS'를 출시했습니다.
- 2023년 10월: F. 호프만 라 로슈(F. Hoffman-La Roche), Ibex Medical Analytics, Amazon Web Services가 제휴하여 전립선암 및 혈액암을 위한 AI 기반 진단 툴을 확장했습니다.
- 2024년 4월: 미국 소재 생명공학 기업 노벨나(Novelna)는 18가지 조기 암을 정확하게 검출할 수 있는 혈액 단백질 검사를 개발했습니다.
- 2023년 5월: 화이자와 써모피셔 사이언티픽은 30개국 이상에서 차세대 염기서열 분석(NGS) 기반 암 진단에 대한 접근성을 향상시키기 위해 제휴를 맺었습니다.
- 2024년 4월: 바이오 래드 연구소는 바이오마커 기반 진단을 위한 'ddPLEX ESR1 돌연변이 검출 키트'를 출시했습니다.
세분화 분석
제품별:
- 분석 키트 및 시약은 진단 검사 수 증가와 신제품 출시로 인해 2026년 83.07%의 시장 점유율을 차지하며 시장을 주도할 것으로 예측됩니다.
- 의료비 지출 증가를 배경으로 의료기기 시장은 꾸준히 성장할 것으로 예측됩니다.
기술별:
- 면역측정법은 유방암, 전립선암, 기타 암 진단에 대한 효과로 시장을 선도하고 있습니다.
- IHC는 정밀한 진단 및 치료 예측 능력에 힘입어 가장 빠른 성장이 기대되는 분야입니다.
유형별:
- 조직 생검은 높은 정확도와 상세한 분자 프로파일링으로 인해 2026년 87.04%의 시장 점유율을 차지하며 시장을 독점할 것으로 예측됩니다.
- 액체 생검은 결과 산출 속도가 빠르고(조직 생검보다 26.8일 빠른 경우가 많음), 가장 빠르게 성장하고 있습니다.
암 유형:
- 유방암 부문은 전 세계적으로 높은 발병률을 반영하여 여전히 지배적인 위치를 유지하고 있습니다.
- 젊은 층의 흡연율 증가로 인해 폐암 시장은 빠르게 성장하고 있습니다.
최종 사용자별:
- 임상검사실은 검사 건수가 많고 기술적으로 고도의 장비를 갖추고 있어 시장을 독점하고 있습니다.
- 병원 및 진료소도 확대되고 있으며, 동일 시설 내에서 진단과 치료를 모두 제공합니다.
지역별 전망
- 북미는 2025년 36.81% 시장 점유율(63억 5,000만 달러)로 시장을 주도할 것으로 예상되며, Thermo Fisher Scientific, Abbott, Illumina, GE Healthcare 등의 기업들에 힘입어 2026년에는 69억 달러에 달할 것으로 전망됩니다.
- 유럽은 2025년 52억 8,000만 달러, 2026년에는 56억 3,000만 달러에 달할 것으로 예상되며, 파트너십과 '10만 유전체 프로젝트'와 같은 유전체 프로젝트가 이를 뒷받침하고 있습니다.
- 아시아태평양은 중국, 일본, 인도 등 국가들의 암 부담 증가에 따라 2025년 37억 8,000만 달러로 성장하고 2026년에는 40억 7,000만 달러에 달할 것으로 예측됩니다.
- 라틴아메리카와 중동 및 아프리카는 규모는 작지만 성장 시장으로, 2025년 시장 규모는 각각 11억 3,000만 달러, 6억 9,000만 달러로 평가되고 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 암 진단 시장 분석, 인사이트 및 예측, 2021년-2034년
제6장 북미의 암 진단 시장 분석, 인사이트 및 예측, 2021년-2034년
제7장 유럽의 암 진단 시장 분석, 인사이트 및 예측, 2021년-2034년
제8장 아시아태평양의 암 진단 시장 분석, 인사이트 및 예측, 2021년-2034년
제9장 라틴아메리카의 암 진단 시장 분석, 인사이트 및 예측, 2021년-2034년
제10장 중동 및 아프리카의 암 진단 시장 분석, 인사이트 및 예측, 2021년-2034년
제11장 경쟁 분석
LSH 26.05.14Growth Factors of cancer diagnostics Market
The global cancer diagnostics market is witnessing robust growth due to the rising burden of cancer, technological advancements in diagnostics, and increasing government initiatives promoting early detection. According to recent data, the market size was valued at USD 17.24 billion in 2025, and it is projected to reach USD 18.51 billion in 2026. By 2034, the market is expected to expand significantly to USD 38.27 billion, exhibiting a CAGR of 9.5% from 2026 to 2034.
Market Drivers
The increasing prevalence of cancers such as breast, colorectal, and prostate cancer is a primary driver fueling the demand for effective diagnostics. For instance, as per the World Health Organization (WHO), global new cancer cases are projected to reach 35 million by 2050, a 77% increase from 20 million in 2022. Early and precise diagnosis plays a critical role in reducing mortality rates, which has accelerated the adoption of advanced diagnostic solutions, including immunohistochemistry (IHC), in-situ hybridization (ISH), molecular diagnostics, and liquid biopsies.
Government and private organizations have increased initiatives to raise awareness regarding early cancer detection. Programs such as Against Colorectal Cancer in Our Neighborhoods (ACCION) in the U.S., Bowel Cancer Screening Programme (BCSP) in the U.K., and WHO's Global Strategy for Cervical Cancer Elimination aim to expand screening and early intervention efforts. These initiatives are boosting market growth by promoting diagnostic adoption.
Market Restraints
Despite growth, high costs and certain risks associated with diagnostic procedures remain challenges. For example, colonoscopy, a gold standard for colorectal cancer screening, carries risks like bleeding, perforation, and device-associated infections. Additionally, advanced diagnostic instruments such as PCR machines can range from USD 3,000 to USD 30,000, with ongoing maintenance costs, which limits adoption, especially in emerging markets.
Market Opportunities
Emerging markets in Asia Pacific are presenting lucrative opportunities for growth due to increasing government investment in healthcare infrastructure and rising awareness about telemedicine. The COVID-19 pandemic accelerated telemedicine adoption, enabling cancer screening and consultations remotely. This trend is expected to continue, providing access to underserved populations for early diagnosis and follow-ups.
Market Trends
Market players are increasingly focusing on product launches, technological advancements, and partnerships. Notable developments include:
- June 2022: F. Hoffmann-La Roche Ltd launched BenchMark ULTRA PLUS to enhance timely cancer diagnosis.
- October 2023: Partnership between F. Hoffmann-La Roche Ltd, Ibex Medical Analytics, and Amazon Web Services to expand AI-powered diagnostic tools for prostate and blood cancers.
- April 2024: Novelna, a U.S.-based biotech company, developed a blood protein test capable of detecting 18 early-stage cancers with high accuracy.
- May 2023: Pfizer Inc. and Thermo Fisher Scientific Inc. collaborated to enhance accessibility to NGS-based cancer diagnostics in over 30 countries.
- April 2024: Bio-Rad Laboratories, Inc. launched the ddPLEX ESR1 Mutation Detection Kit for biomarker-based diagnostics.
Segmentation Analysis
By Product:
- Assay kits & reagents dominate with 83.07% market share in 2026 due to the increasing number of diagnostic tests and new product launches.
- Instruments are projected to grow steadily, driven by rising healthcare expenditures.
By Technique:
- Immunoassays lead the market due to their efficacy in diagnosing breast, prostate, and other cancers.
- IHC is anticipated to grow fastest, supported by precise diagnosis and treatment prediction capabilities.
By Type:
- Tissue biopsy dominates with 87.04% market share in 2026, attributed to high accuracy and detailed molecular profiling.
- Liquid biopsy is growing fastest due to faster result output, often 26.8 days quicker than tissue biopsies.
By Cancer Type:
- Breast cancer segment remains dominant, reflecting the high global burden.
- Lung cancer is growing rapidly due to increasing smoking prevalence among youth.
By End-user:
- Clinical laboratories dominate the market due to high testing volumes and technologically advanced equipment.
- Hospitals & clinics are also expanding, offering both diagnosis and treatment at the same location.
Regional Outlook
- North America dominated in 2025 with 36.81% market share (USD 6.35 billion), projected to reach USD 6.9 billion in 2026, driven by companies like Thermo Fisher Scientific, Abbott, Illumina, and GE Healthcare.
- Europe contributed USD 5.28 billion in 2025, reaching USD 5.63 billion in 2026, supported by partnerships and genome projects like the 100,000 Genomes Project.
- Asia Pacific grew to USD 3.78 billion in 2025, projected at USD 4.07 billion in 2026, with rising cancer burden in countries like China, Japan, and India.
- Latin America and Middle East & Africa are smaller but growing markets, valued at USD 1.13 billion and USD 0.69 billion in 2025, respectively.
Competitive Landscape
Key players like F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Illumina, Inc., GE Healthcare, BD, bioMerieux SA, Myriad Genetics, Inc., Bio-Rad Laboratories, Inc., and QIAGEN dominate the market. Strategic partnerships, product launches, and technological innovations drive growth and expand market access.
Conclusion
The global cancer diagnostics market is poised for strong growth, reaching USD 38.27 billion by 2034. Increasing cancer prevalence, early detection initiatives, technological advancements, and regional expansion in emerging markets are key growth drivers. Despite challenges such as high costs and limited access in some regions, the market continues to evolve with AI integration, biomarker development, and personalized medicine, offering opportunities for improved patient outcomes worldwide.
Segmentation By Product
- Instruments
- Assay Kits & Reagents
By Technique
- Immunohistochemistry (IHC)
- Immunoassays
- Molecular Diagnostics
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- In-situ Hybridization (ISH)
- Others
- Others
By Type
- Tissue Biopsy
- Liquid Biopsy
By Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
By End-user
- Hospitals & Clinics
- Clinical Laboratories
- Others
By Region
- North America (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country)
- U.S.
- Canada
- Europe (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
- U.K.
- Germany
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
- Japan
- China
- Australia
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
- South Africa
- GCC
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Prevalence of Key Cancer, by Countries/Region in 2025
- 4.2. New Product Launches by Key Players
- 4.3. Recent Industry Developments - Mergers & Acquisitions
- 4.4. Overview of Healthcare Expenditure by Key Countries
- 4.5. Technological Advancements, Diagnostic Instruments & Kits
- 4.6. Impact of COVID-19 on the Cancer Diagnostics Market
5. Global Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Product
- 5.1.1. Instruments
- 5.1.2. Assay Kits & Reagents
- 5.2. Market Analysis, Insights and Forecast - By Technique
- 5.2.1. Immunohistochemistry (IHC)
- 5.2.2. Immunoassays
- 5.2.3. Molecular Diagnostics
- 5.2.3.1. Next Generation Sequencing (NGS)
- 5.2.3.2. Polymerase Chain Reaction (PCR)
- 5.2.3.3. In-situ Hybridization (ISH)
- 5.2.3.4. Others
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - By Type
- 5.3.1. Tissue Biopsy
- 5.3.2. Liquid Biopsy
- 5.4. Market Analysis, Insights and Forecast - By Cancer Type
- 5.4.1. Lung Cancer
- 5.4.2. Breast Cancer
- 5.4.3. Colorectal Cancer
- 5.4.4. Prostate Cancer
- 5.4.5. Others
- 5.5. Market Analysis, Insights and Forecast - By End User
- 5.5.1. Hospitals & Clinics
- 5.5.2. Clinical Laboratories
- 5.5.3. Others
- 5.6. Market Analysis, Insights and Forecast - By Geography
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Product
- 6.1.1. Instruments
- 6.1.2. Assay Kits & Reagents
- 6.2. Market Analysis, Insights and Forecast - By Technique
- 6.2.1. Immunohistochemistry (IHC)
- 6.2.2. Immunoassays
- 6.2.3. Molecular Diagnostics
- 6.2.3.1. Next Generation Sequencing (NGS)
- 6.2.3.2. Polymerase Chain Reaction (PCR)
- 6.2.3.3. In-situ Hybridization (ISH)
- 6.2.3.4. Others
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast - By Type
- 6.3.1. Tissue Biopsy
- 6.3.2. Liquid Biopsy
- 6.4. Market Analysis, Insights and Forecast - By Cancer Type
- 6.4.1. Lung Cancer
- 6.4.2. Breast Cancer
- 6.4.3. Colorectal Cancer
- 6.4.4. Prostate Cancer
- 6.4.5. Others
- 6.5. Market Analysis, Insights and Forecast - By End User
- 6.5.1. Hospitals & Clinics
- 6.5.2. Clinical Laboratories
- 6.5.3. Others
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Product
- 7.1.1. Instruments
- 7.1.2. Assay Kits & Reagents
- 7.2. Market Analysis, Insights and Forecast - By Technique
- 7.2.1. Immunohistochemistry (IHC)
- 7.2.2. Immunoassays
- 7.2.3. Molecular Diagnostics
- 7.2.3.1. Next Generation Sequencing (NGS)
- 7.2.3.2. Polymerase Chain Reaction (PCR)
- 7.2.3.3. In-situ Hybridization (ISH)
- 7.2.3.4. Others
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast - By Type
- 7.3.1. Tissue Biopsy
- 7.3.2. Liquid Biopsy
- 7.4. Market Analysis, Insights and Forecast - By Cancer Type
- 7.4.1. Lung Cancer
- 7.4.2. Breast Cancer
- 7.4.3. Colorectal Cancer
- 7.4.4. Prostate Cancer
- 7.4.5. Others
- 7.5. Market Analysis, Insights and Forecast - By End User
- 7.5.1. Hospitals & Clinics
- 7.5.2. Clinical Laboratories
- 7.5.3. Others
- 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Spain
- 7.6.5. Italy
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Product
- 8.1.1. Instruments
- 8.1.2. Assay Kits & Reagents
- 8.2. Market Analysis, Insights and Forecast - By Technique
- 8.2.1. Immunohistochemistry (IHC)
- 8.2.2. Immunoassays
- 8.2.3. Molecular Diagnostics
- 8.2.3.1. Next Generation Sequencing (NGS)
- 8.2.3.2. Polymerase Chain Reaction (PCR)
- 8.2.3.3. In-situ Hybridization (ISH)
- 8.2.3.4. Others
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast - By Type
- 8.3.1. Tissue Biopsy
- 8.3.2. Liquid Biopsy
- 8.4. Market Analysis, Insights and Forecast - By Cancer Type
- 8.4.1. Lung Cancer
- 8.4.2. Breast Cancer
- 8.4.3. Colorectal Cancer
- 8.4.4. Prostate Cancer
- 8.4.5. Others
- 8.5. Market Analysis, Insights and Forecast - By End User
- 8.5.1. Hospitals & Clinics
- 8.5.2. Clinical Laboratories
- 8.5.3. Others
- 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. Australia
- 8.6.4. India
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Product
- 9.1.1. Instruments
- 9.1.2. Assay Kits & Reagents
- 9.2. Market Analysis, Insights and Forecast - By Technique
- 9.2.1. Immunohistochemistry (IHC)
- 9.2.2. Immunoassays
- 9.2.3. Molecular Diagnostics
- 9.2.3.1. Next Generation Sequencing (NGS)
- 9.2.3.2. Polymerase Chain Reaction (PCR)
- 9.2.3.3. In-situ Hybridization (ISH)
- 9.2.3.4. Others
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast - By Type
- 9.3.1. Tissue Biopsy
- 9.3.2. Liquid Biopsy
- 9.4. Market Analysis, Insights and Forecast - By Cancer Type
- 9.4.1. Lung Cancer
- 9.4.2. Breast Cancer
- 9.4.3. Colorectal Cancer
- 9.4.4. Prostate Cancer
- 9.4.5. Others
- 9.5. Market Analysis, Insights and Forecast - By End User
- 9.5.1. Hospitals & Clinics
- 9.5.2. Clinical Laboratories
- 9.5.3. Others
- 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Product
- 10.1.1. Instruments
- 10.1.2. Assay Kits & Reagents
- 10.2. Market Analysis, Insights and Forecast - By Technique
- 10.2.1. Immunohistochemistry (IHC)
- 10.2.2. Immunoassays
- 10.2.3. Molecular Diagnostics
- 10.2.3.1. Next Generation Sequencing (NGS)
- 10.2.3.2. Polymerase Chain Reaction (PCR)
- 10.2.3.3. In-situ Hybridization (ISH)
- 10.2.3.4. Others
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast - By Type
- 10.3.1. Tissue Biopsy
- 10.3.2. Liquid Biopsy
- 10.4. Market Analysis, Insights and Forecast - By Cancer Type
- 10.4.1. Lung Cancer
- 10.4.2. Breast Cancer
- 10.4.3. Colorectal Cancer
- 10.4.4. Prostate Cancer
- 10.4.5. Others
- 10.5. Market Analysis, Insights and Forecast - By End User
- 10.5.1. Hospitals & Clinics
- 10.5.2. Clinical Laboratories
- 10.5.3. Others
- 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 10.6.1. South Africa
- 10.6.2. GCC
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Profiles of Players Operating in the Market
- 11.2.1. F. Hoffmann-La Roche Ltd
- 11.2.1.1. Overview
- 11.2.1.2. Products & services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Thermo Fisher Scientific Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products & services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Abbott
- 11.2.3.1. Overview
- 11.2.3.2. Products & services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Illumina, Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products & services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. GE Healthcare
- 11.2.5.1. Overview
- 11.2.5.2. Products & services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. BD
- 11.2.6.1. Overview
- 11.2.6.2. Products & services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. bioMerieux SA
- 11.2.7.1. Overview
- 11.2.7.2. Products & services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Myriad Genetics, Inc
- 11.2.8.1. Overview
- 11.2.8.2. Products & services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Bio-Rad Laboratories, Inc.
- 11.2.9.1. Overview
- 11.2.9.2. Products & services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. QIAGEN
- 11.2.10.1. Overview
- 11.2.10.2. Products & services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.1. F. Hoffmann-La Roche Ltd
